Requires Medicaid to provide comprehensive coverage for the treatment of obesity including coverage for intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medication.
Summary
Bill A02715 seeks to amend the social services law in New York to expand Medicaid coverage for the treatment of obesity. This includes comprehensive coverage for intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medications. The bill stipulates that these services must be provided by licensed healthcare practitioners and establishes that coverage criteria for medications cannot be more restrictive than FDA-approved indications. Furthermore, it ensures that the coverage for obesity treatment aligns with other medical conditions in terms of deductibles and copayment factors.
Impact
If enacted, this bill would significantly alter Medicaid's coverage policies in New York, mandating that obesity treatment be treated equivalently to other medical conditions. This could lead to increased access to necessary treatments for individuals suffering from obesity, potentially improving health outcomes and reducing long-term healthcare costs associated with obesity-related conditions. The bill also requires Medicaid to inform enrollees about these new coverage provisions, enhancing transparency.
Sentiment
The sentiment surrounding Bill A02715 appears to be supportive, as it addresses a significant public health issue by expanding access to obesity treatment. However, there may be concerns regarding the financial implications for the Medicaid program and the potential for increased utilization of services, which could lead to higher costs for the state.
Contention
Notable points of contention may arise from stakeholders concerned about the fiscal impact of expanding Medicaid coverage. Some legislators and budget analysts may argue that the additional costs associated with comprehensive obesity treatment could strain the state's budget. Conversely, advocates for public health and obesity treatment may contend that the long-term savings from improved health outcomes justify the initial investment.
Requires comprehensive coverage for treatment of obesity, including coverage for prevention and wellness, nutrition counseling, intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medication.
Requires comprehensive coverage for treatment of obesity, including coverage for prevention and wellness, nutrition counseling, intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medication.
Authorizes office of health and human services (EOHHS) to establish coverage for obesity treatments, including medication. Office of health and human services would seek a 1115(a) waiver.
Relates to requiring Medicaid coverage of FDA-approved GLP-1 receptor agonist medications for obesity, metabolic disorders, and autism-related compulsive eating behaviors.